Tests BMS-986500 alone or with other drugs in advanced cancers
Tests the drug BMS-986500 in adults with advanced solid tumors and breast cancer.
Plain-language title generated from the registry record
Registry title: A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Key facts
- Where
- Chuo Ku, Hirakata, Kashiwa, and Koto-ku, JapanSee the 4 sites
- Phase
- Phase 1
Where in Japan
- National Cancer Center HospitalChuo Ku, JapanTaking people
- Kansai Medical University HospitalHirakata, JapanTaking people
- National Cancer Center Hospital EastKashiwa, JapanTaking people
- The Cancer Institute Hospital of JFCRKoto-ku, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06997029EU 2025-524334-26-01
- Record updated
- 6 October 2026
- Original description
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.Read full original descriptionShow less
A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Inclusion: Participants must be ≥ 18 years of age; Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy; Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1; For Part 2A only, participants must have CCNE1-amplified ovarian cancer.
Exclusion: Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months; Participants must not have impaired cardiac function or clinically significant cardiac disease; Participants must not have an active brain metastasis; Participants must not have Grade ≥ 2 peripheral neuropathy; Other protocol-defined Inclusion/Exclusion criteria apply.